# A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)

> **NCT01507402** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 76 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** REGN1033(SAR391786)
- **DRUG:** REGN1033(SAR391786)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01507402
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2012-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01507402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01507402, "A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01507402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*